Compare Heron Therapeutics Inc (HRTX) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.64. The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | VTIP | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | — |
52-Week High | $1.96 | $50.75 |
52-Week Low | $0.39 | $49.39 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
VTIP trades at $49.665, down 0.07% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The ETF focuses on short-term inflation-protected securities, offering a hedge against rising costs. Recent institutional buying includes a 239.8% position increase by Cwm LLC as of April 2026, signaling confidence. A dividend of $0.68 is scheduled for July 2026, providing income appeal.
Outlook remains cautious as the Fed signals no rate cuts in 2026, potentially limiting bond upside. VTIP's inflation hedge is relevant with CPI at 3.8% in April 2026, but short-term rate sensitivity poses risks. The ETF suits defensive portfolios seeking inflation protection, though volatility may persist amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
